Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: jerryriti who wrote (966)	9/1/1999 12:35:00 PM
From: Barbara Bullard	Respond to of 1728

AFFX just got a great plug on the biotech selections on CNBC...I especially liked his comment about the great management and the breadth of the implications of their gene chip. Barbar B

To: jerryriti who wrote (966)	9/1/1999 1:10:00 PM
From: jerryriti	Respond to of 1728

Wednesday September 1, 11:22 am Eastern Time RESEARCH ALERT-Biotech price targets upped by CSFB NEW YORK, Sept 1 (Reuters) - Credit Suisse First Boston said Wednesday that analyst Alex To raised his price targets on three biotechnology companies, citing positive product developments and profit outlooks for the firms. -- Raised 12-month price target for MedImmune (Nasdaq:MEDI - news) to $150 from $92. -- Said target based on ``70 multiple of our 2000 EPS estimate,' of $2.06, and a ``50 multiple of our 2001 EPS estimate.' The 2001 EPS was not specified. -- Said company's antiviral drug Synagis, for preventing lower respiratory tract disease in children, could see a major jump in U.S. sales growth -- 80 percent -- due to strong seasonal demand from November to April, 1999-2000. -- Said raised 1999/2000 seasonal sales growth to $380 million from $315 million previously, and growth for 2000/2001 season to $530 million from $440 million previously. -- Said upped 1999 EPS view to $1.12 from $1.03, and 2000 to $2.06 from $1.83. -- Said upped Affymetrix (Nasdaq:AFFX - news) 12-month price target to $150 from previous $95. -- Cited accelerated growth trend in sales of company's gene chip sequencer business as firm's manufacturing capacity takes off over next 12 months. -- Said company on target to become profitable by end of 2000. -- Said raised Human Genome Sciences (Nasdaq:HGSI - news) price target to $90 from $70 -- Cited expanding value of company's patents covering gene's linked to diseases and product developments that are ``progressing well.' -- Shares of MedImmune rose 5-15/16 to 109-1/8, while shares of Affymetrix rose 4 to 89-5/8. Shares of Human Genome Sciences climbed 3 to 71-1/16.